What are the potential benefits and risks associated with using non-vitamin K oral anticoagulants in patients with atrial fibrillation?
Non-vitamin K oral anticoagulants (NOACs) have been found to have potential benefits including a decreased risk of stroke, reduced intracranial bleeding, and a lower risk of major bleeding. However, NOACs also have potential risks associated with their use, including an increased risk of thromboembolic events, and potential drug interactions with other medications. Additionally, NOACs may be associated with a higher risk of major bleeding compared to warfarin.